Opinion|Videos|July 3, 2024
Review of CLEAR and CheckMate-9ER: Four-Year and 55 Month Follow-Up Data
Author(s)Matthew T. Campbell, MD, MS, Rana R. McKay, MD
Matthew Campbell, MD, MS, analyzes the crucial efficacy and safety results from the CLEAR trial's 4-year final analysis, incorporating insights on how these findings influence clinical decision-making for treatment-naïve patients with advanced renal cell carcinoma.
Advertisement
Episodes in this series
- Dr Campbell: Please briefly review key efficacy and safety data from the CLEAR trial 4-year final analysis (
Motzer et al. J Clin Oncol. 2024 ),
- What are the clinical implications of these data for treatment-naïve patients with advanced RCC?
- In responders, how important is the durability of the response (OS) based on the original response (CR, PR with ≥75% reduction, PR with ≥30% to <75% reduction) for both the intermediate/poor and favorable-risk group?
Advertisement
Related to this article
Experts debate second-line tivozanib for advanced renal cell carcinoma, weighing PFS gains, tolerability, and whether continuing immunotherapy adds real benefit.
Experts weigh IO-TKI vs dual immunotherapy for metastatic ccRCC, highlighting rapid symptom relief, bone/brain response, survival outcomes, and toxicity tradeoffs.
Daniel Heng, MD, discusses how belzutifan plus lenvatinib fills an unmet need after immunotherapy in RCC, with insights on managing hypoxia and anemia and on sequencing.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
2026 AACR Report Highlights Advances and New Directions in Cancer Treatment
2
Amivantamab vs. Emerging EGFR Bispecifics in HNSCC
3
ESMO 2026 Preview: Late-Breaking Studies to Watch Across Tumor Types
4
Retlirafusp Alfa Improves Overall Survival in Phase 3 Trial of HER2– Gastric Cancer
5